

### REMARKS

Claims 1-56 were pending. In the Office Action dated November 6, 2002, the Examiner withdrew claims 6, 7, 9, 11, 13, 15, 17, 19, 21, 23-35, and 54-56 from consideration, and rejected claims 1-5, 8, 10, 12, 14, 16, 18, 20, 22, and 36-53. Applicants have cancelled claims 1-56 and added claims 57-78 herein. Accordingly, claims 57-78 are pending. Applicants respectfully request consideration and allowance of claims 57-78 in view of the following remarks.

Applicants have amended the paragraph beginning at page 18, line 17 to page 19, line 8 to correct the dwf7-1 and dwf7-2 polypeptide sizes recited therein. Applicants note that the paragraph at page 18, line 17 to page 19, line 8 inadvertently transposed the respective sizes of the dwf7-1 and dwf7-2 polypeptides. Applicants note that the dwf7-1 polypeptide, which results from a stop codon in exon 3 of the *dwf7* polynucleotide, is 230 amino acids in length, while the dwf7-2 polypeptide, which results from a stop codon in exon 1 of the *dwf7* polynucleotide, is 60 amino acids in length. The specification repeatedly sets forth the correct sizes of the dwf7-1 and dwf7-2 polypeptides. See p. 7-8, Brief Description of Figures 6, 7, 8A-8D, and 9; Figures 6-9; p. 4, lines 26-30, noting the "premature stop codons in the first (*dwf7-2*) and the third (*dwf7-1*) exons;" and p. 45, lines 4-7; p. 54, lines 23-26; and p. 57, lines 22-24. Accordingly, Applicants request that the paragraph beginning at page 18, line 17 to page 19, line 8 be amended to conform this paragraph to the remainder of the specification.

#### Rejections under 35 U.S.C. § 112, 1<sup>st</sup> paragraph

##### Written Description

The Examiner rejected claims 1, 8, 10, 12, 14, 16, 52 and 53 as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, has possession of the claimed invention. Without acquiescing in the rejection, Applicants have cancelled these claims, thereby mooting the rejection. New claims 57-78 do not recite polynucleotides having 15 contiguous nucleotides of SEQ ID NO:20. Accordingly, new claims 57-78 are believed to have

Applicant : Sunghwa Choe, et al.  
Serial No. : 09/775,879  
Filed : February 2, 2001  
Page : 8 of 8

Attorney's Docket No.: 11696-069001  
2008-55300-US-U-00002.01

proper written description in the specification. The Examiner is requested to withdraw the rejection under 35 U.S.C. § 112, 1<sup>st</sup> paragraph.

#### Enablement

The Examiner rejected claims 1-5, 8, 10, 12, 14, 16, 18, 20, 22, and 36-53 for lack of enablement. Without acquiescing in the rejection, Applicants have cancelled these claims, thereby mooted the rejection. New claims 57-78 are directed to coding sequences and isolated nucleic acids and polynucleotides enabled by the present specification. The Examiner is requested to withdraw the rejection under 35 U.S.C. § 112, 1<sup>st</sup> paragraph.

#### Conclusion

In light of the above, Applicants respectfully request consideration and allowance of claims 57-78.